Impact of vaccination on kinetics of neutralizing antibodies against SARS-CoV-2 by serum live neutralization test based on a prospective cohort

References

• Status of COVID-19 vaccines within WHO EUL/PQ evaluation process. https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_02March2022.pdf>.
   Google Scholar
• Tanriover MD, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398:213–222.
   PubMed Web of Science ®Google Scholar
• Jara A, Undurraga EA, González C, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N Engl J Med. 2021;385:875–884.
   PubMed Web of Science ®Google Scholar
• Mousa M, Albreiki M, Alshehhi F, et al. Similar effectiveness of the inactivated vaccine BBIBP-CorV (Sinopharm) and the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19 related hospitalizations during the Delta outbreak in the United Arab Emirates. J Travel Med. 2022;Mar 4:taac036.
   Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. . 2021;384:403–416.
   PubMed Web of Science ®Google Scholar
• Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19. N. Engl. J. Med. 2021;384:2187–2201.
   PubMed Web of Science ®Google Scholar
• Sahin U, Muik A, Vogler I, et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature. 2021 Jul;595(7868):572–577.
   PubMed Web of Science ®Google Scholar
• Vacharathit V, Srichatrapimuk S, Manopwisedjaroen S, et al. SARS-CoV-2 neutralizing antibodies decline over one year and patients with severe COVID-19 pneumonia display a unique cytokine profile. Int J Infect Dis. 2021 Nov;112:227–234.
   PubMed Web of Science ®Google Scholar
• Collier AY, Brown CM, McMahan KA, et al. Characterization of immune responses in fully vaccinated individuals after breakthrough infection with the SARS-CoV-2 Delta variant. Sci Transl Med. 2022, Apr 20;14(641):eabn6150.
   PubMed Web of Science ®Google Scholar
• Goldberg Y, Mandel M, Bar-On YM, et al. Waning immunity after the BNT162b2 vaccine in Israel. N Engl J Med. 2021;385:e85.
   PubMed Web of Science ®Google Scholar
• Levin EG, Lustig Y, Cohen C, et al. Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 months. N Engl J Med. 2021;385:e84.
   PubMed Web of Science ®Google Scholar
• Singh J, Rahman SA, Ehtesham NZ, et al. SARS- CoV-2 variants of concern are emerging in India. Nat Med. 2021;27:1131–1133.
   PubMed Web of Science ®Google Scholar
• Callaway E. Delta coronavirus variant: scientists brace for impact. Nature. 2021;595:17–18.
   PubMed Web of Science ®Google Scholar
• Tostanoski LH, Yu J, Mercado NB, et al. Immunity elicited by natural infection or Ad26.COV2.S vaccination protects hamsters against SARS-CoV-2 variants of concern. Sci Transl Med. 2021, Nov 3;13(618):eabj3789.
   PubMed Web of Science ®Google Scholar
• Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7). 2020. Chinese Medical Journal (English), 1087-1088-1089-1090-1091-1092-1093-1094-1095.
   Google Scholar
• Goldblatt D. SARS-CoV-2: from herd immunity to hybrid immunity. Nat Rev Immunol Jun. 2022;22(6):333–334.
   PubMed Web of Science ®Google Scholar
• Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat Rev Immunol. Aug. 2021;21(8):475–484.
   PubMed Web of Science ®Google Scholar
• Cromer D, Juno JA, Khoury D, et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat Rev Immunol. 2021 Jun;21(6):395–404.
   PubMed Web of Science ®Google Scholar
• Shamier MC, et al. Virological characteristics of SARS-CoV-2 vaccine breakthrough infections in health care workers. Preprint at medRxiv. 2021; doi:10.1101/2021.08.20.21262158.
   Google Scholar
• Zhao H, Tu H, Yu X, et al. Delayed clearance of viral RNA in sputum for severity COVID-19 patients with initial high viral load. Infect Drug Resist. 2022 Apr 20;15:1971–1979.
   PubMed Web of Science ®Google Scholar
• Nguyen-Contant P, Embong AK, Kanagaiah P, et al. S ProteinReactive IgG and memory B cell production after human SARS-CoV-2 infection includes broad reactivity to the S2 subunit. mBio. 2020;11:e01991–20.
   PubMed Web of Science ®Google Scholar
• Garcia-Beltran WF, Lam EC, Astudillo MG, et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell. 2021 Jan 21;184(2):476–488.e11.
   PubMed Web of Science ®Google Scholar
• Maciola AK, La Raja M, Pacenti M, et al. Neutralizing antibody responses to SARS-CoV-2 in recovered COVID-19 patients are variable and correlate with disease severity and receptor-binding domain recognition. Front Immunol. 2022 Jan 31;13:830710.
   PubMed Web of Science ®Google Scholar
• McMahan K, Yu J, Mercado NB, et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science. 2020;369:812–817.
   PubMed Web of Science ®Google Scholar
• Lipsitch M, Krammer F, Regev-Yochay G, et al. SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. Nat Rev Immunol. 2022 Jan;22(1):57–65.
   PubMed Web of Science ®Google Scholar
• Davis C, Logan N, Tyson G, et al. COVID-19 DeplOyed VaccinE (DOVE) cohort study investigators. reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. PLoS Pathog. 2021, Dec 2;17(12):e1010022.
   PubMed Web of Science ®Google Scholar
• Evans JP, Zeng C, Carlin C, et al. Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection. Sci Transl Med. 2022, Mar 23;14(637):eabn8057.
   PubMed Web of Science ®Google Scholar
• Ai J, Zhang H, Zhang Y, et al. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Emerg Microbes Infect. 2022, Dec;11(1):337–343.
   PubMed Web of Science ®Google Scholar
• Ma C, Chen X, Mei F, et al. Drastic decline in sera neutralization against SARS-CoV-2 Omicron variant in Wuhan COVID-19 convalescents. Emerg Microbes Infect. 2022, Dec;11(1):567–572.
   PubMed Web of Science ®Google Scholar
• Tarkowski M, de Jager W, Schiuma M, et al. Anti-SARS-CoV-2 immunoglobulin isotypes, and neutralization activity against viral variants, according to BNT162b2-vaccination and infection history. Front Immunol. 2021, Dec 17;12:793191.
   PubMed Web of Science ®Google Scholar
• Jalkanen P, Kolehmainen P, Häkkinen HK, et al. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. Nat Commun. 2021;12(1):3991.
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Arashiro T, Adachi Y, et al. Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants. Med (N Y). 2022 Apr 8;3(4):249–261.e4.
   PubMedGoogle Scholar
• Servellita V, Syed AM, Morris MK, et al. Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants. Cell. 2022 Apr 28;185(9):1539–1548.e5.
   PubMed Web of Science ®Google Scholar
• Wang S, Zou X, Li Z, et al. Analysis of clinical characteristics and virus strains variation of patients infected With SARS-CoV-2 in Jiangsu province-A retrospective study. Front Public Health. 2021;9:791600.
   PubMed Web of Science ®Google Scholar